Reprogramming the future of synthetic biology | Cell therapies | bit.bio
April 14, 2021 | Published on Forbes
bit.bio Co-founder and CFO Florian Schuster, investor and Lyell founder, Rick Klausner, and bit.bio founder and CEO Mark Kotter
John Cumbers, founder and CEO of SynBioBeta, published a piece in Forbes after a conversation with Dr Rick Klausner – bit.bio investor, founder and Executive Chairman of Lyell Immunopharma – and Dr Mark Kotter, bit.bio founder and CEO.
The piece covers how Rick and Mark first met and how bit.bio is reimagining what is possible with the engineering of mammalian cells – industrial-scale cell manufacturing and bringing sustainable cell-culture meats to consumers via Meatable.
“Mark showed up at Lyell and started showing me his beautiful data. I walked out and told my assistant to cancel the morning. It only took four hours for us to decide to write him a check.”
Dr Rick Klausner
bit.bio investor,founder and Executive Chairman of Lyell Immunopharma
“By converting current cell therapies, which at the moment cost hundreds of thousands of dollars, to a model of biologics or perhaps even a small molecule in the future, cell therapies could become common and widespread.”